El interés en corto de ProMIS Neurosciences da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de ProMIS Neurosciences. Los datos de interés en corto se actualizan cada dos semanas.

ProMIS Neurosciences (NASDAQ:PMN) Bolsa, Informe de interés en corto

ProMIS Neurosciences

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.

ProMIS Neurosciences Inc. - Common Shares

ProMIS Neurosciences Inc

Perfect Moment Ltd

PERSEUS MINING LTD ORD by Perseus Mining Ltd

Perseus Mining Ltd

News

CSX Says On July 10, Sec Indicated It Concluded Investigation Into Accounting Restatement, Does Not Intend To Recommend Enforcement Action; Expects Impact Of Applying Provision Related To OBBBA To Result In Favorable Cash Tax Impacts Of About $250M For 2025 Tax Year

Offerings

ADVB

Advanced Biomed  Files For Offering Of Up To 40M Shares Of Common Stock By Selling Stockholder

<a href="https://nypost.com/2025/07/23/media/jeff-bezos-has-been-weighing-a-possible-acquisition-of-cnbc-sources/" title="https://nypost.com/2025/07/23/media/jeff-bezos-has-been-weighing-a-possible-acquisition-of-cnbc-sources/">https://nypost.com/2025/07/23/media/jeff-bezos-has-been-weighing-a-possible-acquisition-of-cnbc-sources/</a>

CMCSA

"Jeff Bezos weighing possible acquisition of CNBC cable network: sources" - NY Post

Mid Penn Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPB#NASDAQ">MPB</a>) reported quarterly earnings of $0.70 per share which beat the analyst consensus estimate of $0.47 by 49.57 percent. This is a 2.94 percent increase over earnings of $0.68 per share from the same period last year. The company reported quarterly sales of $54.349 million which beat the analyst consensus estimate of $53.533 million by 1.52 percent. This is a 23.25 percent increase over sales of $44.095 million the same period last year.

Earnings

Earnings Beats

Mid Penn Bancorp Q2 Adj. EPS $0.70 Beats $0.47 Estimate, Sales $54.349M Beat $53.533M Estimate

Macro Economic Events

Politics

Economics

General

TSLA

During Conference Call, Tesla CEO Elon Musk Says Sales In Europe Will Improve Significantly Once Supervised Full-Self Driving Is Approved; Energy Segment Growing Very Well Despite Headwinds From Tariffs

Citigroup analyst Nicholas Joseph maintains Prologis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLD#NYSE">PLD</a>) with a Buy and lowers the price target from $150 to $140.

Price Target

Analyst Ratings

Citigroup Maintains Buy on Prologis, Lowers Price Target to $140

During Conference Call, Tesla CEO Elon Musk Says Will Probably Have Autonomous Ride Hailing In Probably Half Of The Population Of The US by The End Of Year;  Looking For Robotaxi Regulatory Approvals In San Francisco Bay Area, Nevada, Arizona, Florida And Other Places; Close To Getting Regulatory Approval For Supervised FSD In Netherlands

Declaration of Dividend The Board of Directors declared a quarterly cash dividend of $0.07 per share, payable on August 20, 2025, to shareholders of record as of August 6, 2025.

Dividends

NBBK

NB Bancorp Initiates Quarterly Cash Dividend Of $0.07 Per Share

L3Harris Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LHX#NYSE">LHX</a>) has outperformed the market over the past 10 years by 1.13% on an annualized basis producing an average annual return of 12.85%. Currently, L3Harris Technologies has a market capitalization of $50.87 billion. 
Buying $1000 In LHX: If an investor had bought $1000 of LHX stock 10 years ago, it would be worth $3,373.80 today based on a price of $272.10 for LHX at the time of writing.
<h3>L3Harris Technologies's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1753307119_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$1000 Invested In L3Harris Technologies 10 Years Ago Would Be Worth This Much Today

Southwest Airlines Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>) released its second-quarter results after Wednesday's closing bell. Here's a look at the key figures <a href="https://www.benzinga.com/pressreleases/25/07/n46588037/southwest-airlines-reports-second-quarter-2025-results">from the quarter. </a>
The Details: Southwest Airlines reported quarterly adjusted earnings of 43 cents per share, which missed the Street consensus estimate of 51 cents per share. Quarterly revenue also came in below expectations at $7.24 billion, missing the $7.3 billion analyst estimate.
Read Next:&nbsp; <a href="https://www.benzinga.com/markets/tech/25/07/46505139/quantum-stock-tracker-rigetti-achieves-major-breakthrough-but-jim-cramer-names-another-stock-to-own?utm_source=articleShare">Quantum Stock Tracker: Rigetti Achieves Major Breakthrough, But Jim Cramer Names Another Stock To &#8216;Own&#8217;</a>
The company&#8217;s board of directors authorized a new $2 billion share repurchase program. 
&#8220;While early, recent industry demand shows signs of improvement off of depressed second quarter 2025 levels, which combined with moderated capacity across the industry and Southwest-specific initiatives, creates a constructive backdrop for the second half of the year,&#8221; Southwest wrote in its press release. 
Outlook:&nbsp;Southwest sees third-quarter RASM in a range of&nbsp;down&nbsp;2%&nbsp;to up&nbsp;2% and fuel cost per gallon between&nbsp;$2.40 and $2.50. 
LUV Price Action: According to data from<a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw"> Benzinga Pro</a>, Southwest Airlines stock was down 0.24% at $37.44 in Wednesday's extended trading. 
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/space/25/07/46534529/space-stock-tracker-virgin-galactic-makes-a-comeback-while-rocket-lab-takes-a-breather?utm_source=articleShare">Space Stock Tracker: Virgin Galactic Makes A Comeback While Rocket Lab Takes A Breather</a></li>
</ul>
Photo: Shutterstock

After-Hours Center

Movers

Southwest Airlines Reports Worse-Than-Expected Q2, But Sees 'Constructive Backdrop' For Back Half Of 2025

Citigroup analyst Arthur Truslove maintains Equifax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFX#NYSE">EFX</a>) with a Buy and lowers the price target from $294 to $290.

Citigroup Maintains Buy on Equifax, Lowers Price Target to $290

<a href="https://www.youtube.com/watch?v=sk9Yovro9kE">https://www.youtube.com/watch?v=sk9Yovro9kE</a>
&nbsp;

Global

President Trump Says Will Have Straight Simple Tariffs Of Between 15% And 50% On Countries

On July 22, 2025, the Board of Directors of Oportun Financial Corporation (the "Company") appointed Joseph Schueller, the Company's Senior Vice President, Finance – Controller, as the Company's Principal Financial Officer and Principal Accounting Officer, effective immediately. In connection with Mr. Schueller's appointment, Raul Vazquez, the Company's Chief Executive Officer, will no longer serve in such capacities.

Management

OPRT

Oportun Appoints Joseph Schueller As Principal Financial And Accounting Officer, Replacing CEO Raul Vazquez

Maxim Group analyst Michael Okunewitch downgrades Anebulo Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANEB#NASDAQ">ANEB</a>) from Buy to Hold.

Downgrades

ANEB

Maxim Group Downgrades Anebulo Pharmaceuticals to Hold

<a href="https://www.wsj.com/business/media/nbcu-is-exploring-launching-a-sports-cable-network-92bb2b03" title="https://www.wsj.com/business/media/nbcu-is-exploring-launching-a-sports-cable-network-92bb2b03">https://www.wsj.com/business/media/nbcu-is-exploring-launching-a-sports-cable-network-92bb2b03</a>

"NBCU Is Exploring Launching a Sports Cable Network; The potential cable channel would broadcast sports, including the NBA, also being shown on NBCU's Peacock streaming service" - WSJ Exclusive

BNZI

Banzai International Files For Mixed Shelf Of Up To $30M

Packaging Corp of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PKG#NYSE">PKG</a>) is looking for Q3 GAAP EPS of $2.80 vs $2.81 analyst estimate..

Guidance

Packaging Corp of America Sees Q3 GAAP EPS $2.80 vs $2.81 Est

<a href="https://www.youtube.com/watch?v=sk9Yovro9kE">https://www.youtube.com/watch?v=sk9Yovro9kE</a>

President Trump Says Made Deal With EU; Was Related To Military Equipment

Packaging Corp of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PKG#NYSE">PKG</a>) reported quarterly earnings of $2.48 per share which beat the analyst consensus estimate of $2.42 by 2.39 percent. This is a 12.73 percent increase over earnings of $2.20 per share from the same period last year. The company reported quarterly sales of $2.171 billion which missed the analyst consensus estimate of $2.183 billion by 0.55 percent. This is a 4.64 percent increase over sales of $2.075 billion the same period last year.

Earnings Misses

Packaging Corp of America Q2 Adj. EPS $2.48 Beats $2.42 Estimate, Sales $2.171B Miss $2.183B Estimate

Viking Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) shares are falling in Wednesday&#8217;s after-hours session after the company reported financial results <a href="https://www.benzinga.com/pressreleases/25/07/n46586483/viking-therapeutics-reports-second-quarter-2025-financial-results-and-provides-corporate-update">for the second quarter</a>.
Q2 Earnings: Viking Therapeutics reported a second-quarter loss of 58 cents per share, missing analyst <a href="http://benzinga.com/quote/VKTX/earnings">estimates</a> for a loss of 46 cents per share, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
The clinical-stage biopharmaceutical company said research and development expenses totaled&nbsp;$60.2 million&nbsp;in the second quarter, up from $23.8 million in the prior year&#8217;s quarter. 
Viking Therapeutics ended the period with $808 million in total cash, cash equivalents and short-term investments.
Viking provided several updates on clinical milestones. The company said it recently initiated its VANQUISH Phase 3 registration program and noted that trials are underway for VK2735 in Obesity. Viking also said it completed enrollment of its Phase 2 VENTURE-Oral Dosing trial.
&#8220;We believe the study&#8217;s rapid enrollment speaks to continued strong demand for new and differentiated weight loss therapies. We remain on track to announce top-line data from the VENTURE-Oral study in the second half of the year,&#8221; said Brian Lian, CEO of Viking Therapeutics.
Viking said it continues to make progress&nbsp;on its amylin agonist program with an IND filing expected to be submitted later this year.
The company noted that its cash position is expected to support the advancement of VK2735 through Phase 3 clinical trials,&nbsp;as well as further progress in other key development programs. 
VKTX Price Action: <a href="http://benzinga.com/quote/VKTX">Viking Therapeutics shares</a> were down 6.74% in after-hours, trading at $31.15 at the time of publication Wednesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/downgrades/25/07/46584818/elevidys-halt-sparks-analyst-downgrades-sarepta-races-to-revise-label">Elevidys Halt Sparks Analyst Downgrades—Sarepta Races To Revise Label</a></li>
</ul>
Photo: Shutterstock.

Health Care

VKTX

Viking Therapeutics Stock Slides After Company Misses Q2 Earnings Estimates

Press Releases

ProMIS Neurosciences to Participate in the 37th Annual Roth Conference

ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting

ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer's Disease/Parkinson's Disease 2025 International Conference

Comments

ProMIS Neurosciences

Interés en corto

ProMIS Neurosciences (NASDAQ:PMN) Bolsa, Informe de interés en corto

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL